Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Merck
Medtronic
Dow

Last Updated: June 27, 2022

CLINICAL TRIALS PROFILE FOR SAXENDA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Saxenda

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02488057 ↗ Improving Beta Cell Function in Mexican American Women With Prediabetes Completed Ohio State University Phase 4 2016-05-01 This study will examine the benefits of weight loss alone or in combination with a GLP1 receptor agonist, liraglutide, on beta cell function in young adult Mexican American (MA) women with prediabetes. The Investigators have chosen to focus on MA women because MA women are at very high risk for progression to diabetes and have not traditionally been involved in weight management studies since they are thought to be difficult to recruit and retain in such programs. However, investigators have had particular success in working with young MA women using specifically developed ethnic and gender conscious programs. Because weight loss does not prevent all progression to diabetes, some participants will receive the diabetes medication, liraglutide, which has been shown to stabilize beta cell function. The study will also interrogate for polymorphisms of known T2DM genes to correlate with beta cell response to weight loss and liraglutide treatment. Additionally, this investigation targets serious health disparities in metabolic disease in a highly vulnerable, rapidly growing population, testing novel gender and culturally focused intervention strategies and identifying genetic biomarkers of response to a pharmacologic intervention that targets the pancreatic ßcell. These results will help to a) understand mechanisms of disease, b) personalize treatment through identification of a high risk group that may be amenable to specific therapy, and c) ultimately, sets the stage for an intervention trial to prevent diabetes, a major chronic and costly disease, in Mexican Americans.
NCT02647944 ↗ Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 2 2015-12-18 This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02647944 ↗ Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity Completed Novo Nordisk A/S Phase 2 2015-12-18 This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02647944 ↗ Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity Completed Mayo Clinic Phase 2 2015-12-18 This study was being done to assess the stomach emptying effect of a maximum dose of 3 mg Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a medication approved by the Food and Drug Administration (FDA) for routine clinical use.
NCT02773355 ↗ Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients Enrolling by invitation Novo Nordisk A/S 2016-05-16 This trial is conducted in North America. The aim is to investigate timely detection of pancreatitis cases as well as cases of suspicion of serious and non-serious adverse reactions possibly or probably related to Saxenda® in Mexican patients.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Saxenda

Condition Name

Condition Name for Saxenda
Intervention Trials
Obesity 22
Weight Loss 2
Metabolic Disturbance 1
Pre Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Saxenda
Intervention Trials
Obesity 11
Weight Loss 7
Overweight 3
Prediabetic State 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Saxenda

Trials by Country

Trials by Country for Saxenda
Location Trials
United States 33
Mexico 3
United Kingdom 3
Denmark 3
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Saxenda
Location Trials
Minnesota 4
Texas 4
Ohio 3
Pennsylvania 3
California 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Saxenda

Clinical Trial Phase

Clinical Trial Phase for Saxenda
Clinical Trial Phase Trials
Phase 4 13
Phase 3 3
Phase 2 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Saxenda
Clinical Trial Phase Trials
Completed 13
Active, not recruiting 7
Recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Saxenda

Sponsor Name

Sponsor Name for Saxenda
Sponsor Trials
Novo Nordisk A/S 12
Mayo Clinic 3
Hvidovre University Hospital 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Saxenda
Sponsor Trials
Other 37
Industry 15
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Colorcon
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.